Discovery of MK-8719, a Potent O‑GlcNAcase Inhibitor as a Potential Treatment for Tauopathies

Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. Beginning with carbohydrate-based lead molecules, we pursued an optimization strategy of reducing polar...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2019-11, Vol.62 (22), p.10062-10097
Main Authors: Selnick, Harold G, Hess, J. Fred, Tang, Cuyue, Liu, Kun, Schachter, Joel B, Ballard, Jeanine E, Marcus, Jacob, Klein, Daniel J, Wang, Xiaohai, Pearson, Michelle, Savage, Mary J, Kaul, Ramesh, Li, Tong-Shuang, Vocadlo, David J, Zhou, Yuanxi, Zhu, Yongbao, Mu, Changwei, Wang, Yaode, Wei, Zhongyong, Bai, Chang, Duffy, Joseph L, McEachern, Ernest J
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inhibition of O-GlcNAcase (OGA) has emerged as a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer’s disease and progressive supranuclear palsy. Beginning with carbohydrate-based lead molecules, we pursued an optimization strategy of reducing polar surface area to align the desired drug-like properties of potency, selectivity, high central nervous system (CNS) exposure, metabolic stability, favorable pharmacokinetics, and robust in vivo pharmacodynamic response. Herein, we describe the medicinal chemistry and pharmacological studies that led to the identification of (3aR,5S,6S,7R,7aR)-5-(difluoromethyl)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5H-pyrano­[3,2-d]­thiazole-6,7-diol 42 (MK-8719), a highly potent and selective OGA inhibitor with excellent CNS penetration that has been advanced to first-in-human phase I clinical trials.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.9b01090